Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cardiolipin synthetase, putative | 0.0035 | 0.1973 | 0.5 |
Leishmania major | phosphatidylglycerophosphate synthase, putative | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0083 | 0.8027 | 1 |
Toxoplasma gondii | phospholipase D active site domain-containing protein | 0.0035 | 0.1973 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0064 | 0.5702 | 0.7103 |
Schistosoma mansoni | phospholipase D | 0.0099 | 1 | 0.5 |
Entamoeba histolytica | phospholipase D, putative | 0.0099 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0064 | 0.5702 | 0.7103 |
Onchocerca volvulus | Putative phospholipase D | 0.0019 | 0 | 0.5 |
Echinococcus granulosus | phospholipase D1 | 0.0099 | 1 | 1 |
Trypanosoma brucei | cardiolipin synthetase, putative | 0.0035 | 0.1973 | 0.5 |
Echinococcus multilocularis | phospholipase D | 0.0087 | 0.8562 | 0.8562 |
Echinococcus multilocularis | phospholipase D1 | 0.0099 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0083 | 0.8027 | 1 |
Entamoeba histolytica | phospholipase D, putative | 0.0099 | 1 | 1 |
Brugia malayi | Phospholipase D. Active site motif family protein | 0.0035 | 0.1973 | 0.1973 |
Trypanosoma cruzi | cardiolipin synthetase, putative | 0.0035 | 0.1973 | 0.5 |
Trypanosoma brucei | cardiolipin synthetase | 0.0035 | 0.1973 | 0.5 |
Echinococcus granulosus | phospholipase D | 0.0087 | 0.8562 | 0.8562 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 50 uM | Inhibition of type 1 pili formation in uropathogenic Escherichia coli isolate UTI89 assessed as inhibition of biofilm formation after 24 hrs by crystal violet staining method | ChEMBL. | 22749393 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.